Brokerages Set ProQR Therapeutics N.V. (NASDAQ:PRQR) Price Target at $7.14

ProQR Therapeutics N.V. (NASDAQ:PRQR) has received an average recommendation of “Moderate Buy” from the nine analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $7.1429.

Several equities research analysts have recently commented on PRQR shares. Chardan Capital reaffirmed a “buy” rating and set a $4.00 price target on shares of ProQR Therapeutics in a research report on Tuesday, November 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ProQR Therapeutics in a research report on Wednesday, October 8th. Finally, Zacks Research raised shares of ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 13th.

Institutional Trading of ProQR Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of PRQR. Osaic Holdings Inc. lifted its position in shares of ProQR Therapeutics by 59.6% in the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 4,500 shares in the last quarter. Moody Lynn & Lieberson LLC bought a new stake in ProQR Therapeutics during the 4th quarter valued at approximately $50,000. Fifth Third Bancorp purchased a new position in ProQR Therapeutics in the 3rd quarter worth approximately $64,000. Vontobel Holding Ltd. boosted its stake in ProQR Therapeutics by 76.5% in the 2nd quarter. Vontobel Holding Ltd. now owns 63,979 shares of the biopharmaceutical company’s stock worth $131,000 after purchasing an additional 27,722 shares during the period. Finally, OneDigital Investment Advisors LLC grew its holdings in ProQR Therapeutics by 23.1% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 80,000 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 15,000 shares in the last quarter. 32.65% of the stock is owned by hedge funds and other institutional investors.

ProQR Therapeutics Trading Up 4.3%

Shares of PRQR stock opened at $1.71 on Friday. The stock has a market capitalization of $179.91 million, a P/E ratio of -3.64 and a beta of 0.19. The firm’s 50 day moving average is $2.05 and its 200 day moving average is $2.21. ProQR Therapeutics has a 12-month low of $1.07 and a 12-month high of $3.10.

ProQR Therapeutics (NASDAQ:PRQR) last released its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). The firm had revenue of $3.38 million during the quarter, compared to analysts’ expectations of $7.05 million. ProQR Therapeutics had a negative return on equity of 58.70% and a negative net margin of 273.20%. As a group, equities analysts predict that ProQR Therapeutics will post -0.31 earnings per share for the current year.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.